Trials
Search / Trial NCT06424379

BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.

Launched by HOSPICES CIVILS DE LYON · May 16, 2024

Apply for Trial

Trial Information

Current as of March 14, 2025

Active, not recruiting

Keywords

Non Hodgkin Lymphoma Bcl6 Gene Rearrangement Next Generation Sequencing

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Diagnostic of non-Hodgkin's lymphoma at anatomy and cytology department of Lyon Sud hospital
  • • Rearrangement of the BCL6 gene detected by FISH analysis
  • • Diagnostic of the disease between january 2016 and december 2023
  • Exclusion Criteria:
  • • Patients diagnosed with primary cutaneous centrofollicular B lymphoma, composite lymphoma, anaplastic B lymphoma or primary B lymphoma of the mediastinum.
  • • Presence of a rearrangement of the BLC2 gene or the CMYC gene in FISH
  • • Presence of a non-significant BCL6 gene rearrangement (\<5% of rearranged cells)

About Hospices Civils De Lyon

Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.

Locations

Pierre Bénite, , France

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0